Media headlines about Cantel Medical (NYSE:CMD) have trended positive on Monday, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cantel Medical earned a media sentiment score of 0.28 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.3681497425311 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Cantel Medical (NYSE CMD) traded up $0.76 during midday trading on Monday, reaching $106.84. 81,436 shares of the company’s stock traded hands, compared to its average volume of 154,810. The company has a quick ratio of 1.48, a current ratio of 2.44 and a debt-to-equity ratio of 0.31. Cantel Medical has a 12 month low of $69.21 and a 12 month high of $108.00. The firm has a market cap of $4,470.00, a PE ratio of 59.03 and a beta of 1.25.

The company also recently declared a Semi-Annual dividend, which will be paid on Wednesday, January 31st. Shareholders of record on Wednesday, January 17th will be issued a dividend of $0.085 per share. This represents a yield of 0.17%. The ex-dividend date of this dividend is Tuesday, January 16th. This is a boost from Cantel Medical’s previous Semi-Annual dividend of $0.07. Cantel Medical’s payout ratio is 7.73%.

In other Cantel Medical news, Director George L. Fotiades sold 6,000 shares of the business’s stock in a transaction that occurred on Friday, October 13th. The shares were sold at an average price of $95.23, for a total transaction of $571,380.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Eric W. Nodiff sold 2,868 shares of the business’s stock in a transaction that occurred on Friday, October 20th. The stock was sold at an average price of $97.55, for a total transaction of $279,773.40. Following the transaction, the executive vice president now owns 39,102 shares of the company’s stock, valued at approximately $3,814,400.10. The disclosure for this sale can be found here. Insiders own 12.30% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Favorable News Coverage Somewhat Unlikely to Impact Cantel Medical (CMD) Share Price” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2018/01/08/favorable-news-coverage-somewhat-unlikely-to-impact-cantel-medical-cmd-share-price.html.

Cantel Medical Company Profile

Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.

Insider Buying and Selling by Quarter for Cantel Medical (NYSE:CMD)

Receive News & Ratings for Cantel Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical and related companies with MarketBeat.com's FREE daily email newsletter.